Evolus (EOLS) vs Intercure (INCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Evolus (EOLS) has outperformed Intercure (INCR) over the past year, gaining 25.6% versus a loss of 37.5%. Over five years, EOLS leads with a +1.7% price change compared with -85.8% for INCR. Evolus is the larger company by market cap ($513.9 million vs $75.5 million), about 6.8 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EOLS | INCR |
|---|---|---|
| Share price | $7.78 | $5.03 |
| Market cap | $513.87M | $75.47M |
| 1-day change | -0.26% | -1.95% |
| YTD return | +17.29% | +10.55% |
| 1-year return | +25.60% | -37.52% |
| 5-year return | +1.69% | -85.81% |
| Forward P/E | 26.60 | — |
| EPS (TTM) | $-0.53 | $-0.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.31 | $8.40 |
| 52-week low | $3.86 | $3.40 |
| Distance from 52-week high | -16.43% | -40.12% |
| Analyst consensus | none | — |
| Avg. price target upside | +92.80% | — |
| Average volume | 900.79K | 21.73K |
| Shares outstanding | 66.05M | 15.00M |
| Employees | 353 | 285 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Evolus is about 6.8 times larger than Intercure by market value ($513.87M vs $75.47M).
- EOLS has outperformed INCR by 63.1 percentage points over the past year.
About Evolus
EOLS stock →Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes.
Health Care · Biotechnology: Pharmaceutical Preparations · 353 employees
About Intercure
INCR stock →InterCure Ltd., together with its subsidiaries, engages in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil.
Health Care · Biotechnology: Pharmaceutical Preparations · 285 employees
EOLS vs INCR FAQ
Which is bigger, Evolus or Intercure?
Evolus (EOLS) is larger, with a market capitalization of $513.87M compared with $75.47M for Intercure (INCR).
Which stock has performed better over the past year, EOLS or INCR?
EOLS returned +25.60% over the past 12 months, compared with -37.52% for INCR (price return, excluding dividends). Past performance does not predict future results.
Are Evolus and Intercure in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.